Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2021-05-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于第二届董事会第九次会议独立董事意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the appointment of key management personnel (board secretary and financial director) at Jiangsu Haobo Biopharmaceutical Co., Ltd. It references compliance with company law and stock exchange listing rules, and discusses qualifications and appointment procedures. The content focuses on board/management changes rather than financial results, audit, or other report types. The document length is short and it is not a report or announcement of a report publication. Therefore, it fits best under Board/Management Information (MANG).
2021-05-23 Chinese
江苏浩欧博生物医药股份有限公司关于董事辞职暨变更董事会秘书、财务总监的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a director and changes in the company's board secretary and financial director. It details the resignation, appointment, and qualifications of new board members and senior management. There is no financial data, earnings information, or report attached. The content focuses on management changes, which fits the category of Board/Management Information (MANG). The document length is 2226 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2021-05-23 Chinese
江苏浩欧博生物医药股份有限公司关于自愿披露公司获得医疗器械产品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding the voluntary disclosure of obtaining a medical device product registration certificate. It details the product name, registration certificate number, approval conclusion, and risk warnings. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no meeting materials, no voting results, no management changes, no capital or financing updates, and no legal proceedings. The document is an official announcement about a regulatory approval related to a product, not a financial or governance report. It is short (1001 characters) and serves as a regulatory announcement about product registration. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-05-18 Chinese
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2020年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the procedural legality and validity of the 2020 Annual General Meeting (AGM) of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It discusses the convening, attendance, and voting procedures of the AGM, confirming compliance with relevant laws and company bylaws. The document is not the AGM materials or presentations themselves but a legal opinion related to the AGM. Given the content and purpose, this fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related official documents. The document length is short (2080 characters), but it is a substantive legal opinion, not merely an announcement of a report. Therefore, the classification is AGM-R with high confidence.
2021-05-13 Chinese
江苏浩欧博生物医药股份有限公司2020年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2020 Annual General Meeting (AGM) resolution announcement for Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2020 annual report, financial statements, board and supervisory reports, profit distribution, and other corporate matters. The document includes voting percentages and confirms the legality and validity of the meeting and voting process. It does not contain the full annual report or financial statements themselves but reports on the resolutions passed at the AGM. The document length is 4247 characters, which is relatively short and consistent with an announcement of voting results from an AGM. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-05-13 Chinese
江苏浩欧博生物医药股份有限公司关于召开2020年年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2020 annual performance explanation meeting (业绩说明会) for Jiangsu Hob Biotech Co., Ltd. It references that the 2020 Annual Report has already been disclosed on April 15, 2021, and invites investors to participate in a web-based interactive session on May 17, 2021. The document contains no actual financial data or detailed financial analysis but serves to inform investors about the upcoming event and how to participate. The document length is short (1103 characters) and it is clearly an announcement rather than the report or transcript itself. Therefore, it fits the category of an Investor Presentation announcement or Annual General Meeting related information. However, since it is specifically about an annual performance explanation meeting (业绩说明会), which is a type of investor presentation focused on financial results, the best fitting category is Investor Presentation (IP).
2021-05-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.